Clinical Trial Update: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluated BKM120 (buparlisib) plus cetuximab for recurrent or metastatic head and neck squamous cell carcinoma; results completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• BKM120 (Buparlisib)
• Cetuximab (cetuximab)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-27